A Study to Evaluate the Drug-Drug Interaction of EDP-323 With Midazolam, Caffeine, and Rosuvastatin in Healthy Participants

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

March 13, 2025

Primary Completion Date

June 6, 2025

Study Completion Date

June 13, 2025

Conditions

RSV InfectionDrug Drug Interaction

Interventions

DRUG

EDP-323

Subjects will receive EDP-323 once daily on Days 5-15

DRUG

Midazolam

Subjects will receive midazolam once daily on Days 1 and 12

DRUG

Caffeine

Subjects will receive caffeine once daily on Days 1 and 12

DRUG

Rosuvastatin

Subjects will receive rosuvastatin once daily on Days 2 and 13

Trial Locations (1)

ICON, plc, San Antonio